Polaris Venture Management Co V’s Ocular Therapeutix OCUL Stock Holding History

Polaris Venture Management Co V’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-383,141	Closed	-$3.56M	–	9
2017 Q1	$3.56M	Sell	383,141 -405,582	-51%	-$3.38M	3.81%	8
2016 Q4	$6.6M	Sell	788,723 -209,990	-21%	-$1.63M	7.84%	5
2016 Q3	$6.86M	Hold	998,713	–	–	7.24%	6
2016 Q2	$4.94M	Sell	998,713 -231,296	-19%	-$2.29M	5.31%	8
2016 Q1	$11.9M	Hold	1,230,009	–	–	11.35%	4
2015 Q4	$11.5M	Hold	1,230,009	–	–	9.05%	5
2015 Q3	$17.3M	Hold	1,230,009	–	–	11.78%	5
2015 Q2	$25.9M	Sell	1,230,009 -800,000	-39%	-$19.8M	11.54%	5
2015 Q1	$85.2M	Buy	+2,030,009	New	+$66.7M	38.08%	1

Other funds holding OCUL

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polaris Venture Management Co V's OCUL Position: Q2 2017 in Review

Polaris Venture Management Co V sold out of Ocular Therapeutix (OCUL) in Q2 2017, closing a stake of 383,141 shares — an estimated $3.56M sold.

Polaris Venture Management Co V first reported a position in OCUL in Q1 2015 and held it in 9 quarters. The position peaked at $85.2M in Q1 2015. 72 funds tracked by Wall St. Rank hold OCUL as of Q2 2017.

Polaris Venture Management Co V reported no remaining Ocular Therapeutix position as of Q2 2017 after selling out during the quarter.
Polaris Venture Management Co V sold 383,141 Ocular Therapeutix shares in Q2 2017, an estimated $3.56M.
Polaris Venture Management Co V first reported a position in Ocular Therapeutix in Q1 2015 and held it in 9 quarters.
Polaris Venture Management Co V's Ocular Therapeutix position peaked at $85.2M in Q1 2015.
72 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2017.

Based on Polaris Venture Management Co V's 13F filing for Q2 2017, filed 14 Aug 2017.